Our biofluid-based tests have the potential to deliver on the promise of personalized healthcare. These breakthrough tests are the industry’s first RNA-based liquid biopsies, which are designed to overcome the limitations of currently available tissue-based diagnostics and other liquid biopsies. Our tests leverage the power of exosomes, messengers that are released by all living cells and contain valuable biological information in the form of RNA, DNA and proteins. Our diagnostics are designed to aid clinicians in detecting, diagnosing and monitoring cancer.